Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Cash from Financing Activities (2024 - 2025)

Prelude Therapeutics' Cash from Financing Activities history spans 2 years, with the latest figure at $24.9 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 73464.71% year-over-year to $24.9 million; the TTM value through Dec 2025 reached $24.8 million, up 20780.0%, while the annual FY2025 figure was $24.8 million, 20780.0% up from the prior year.
  • Cash from Financing Activities for Q4 2025 was $24.9 million at Prelude Therapeutics, up from -$5000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $24.9 million in Q4 2025 and bottomed at -$160000.0 in Q1 2025.